VOL. XCIV, NO. 247
★ WIDE MOAT STOCKS COMPARISON ★
NO ADVICE
Wednesday, December 31, 2025
Stock Comparison
Gilead Sciences, Inc. vs UnitedHealth Group Incorporated
Compare moat strength, market structure, and segment coverage to understand how each company defends its edge.
Gilead Sciences, Inc.
GILD · NASDAQ Global Select Market
Weighted average of segment moat scores, combining moat strength, durability, confidence, market structure, pricing power, and market share.
Full stock profile
Dive deeper into Gilead Sciences, Inc.'s moat claims, evidence, and risks.
View GILD analysisUnitedHealth Group Incorporated
UNH · New York Stock Exchange
Weighted average of segment moat scores, combining moat strength, durability, confidence, market structure, pricing power, and market share.
Full stock profile
Dive deeper into UnitedHealth Group Incorporated's moat claims, evidence, and risks.
View UNH analysisComparison highlights
- Moat score gap: Gilead Sciences, Inc. leads (74 / 100 vs 64 / 100 for UnitedHealth Group Incorporated).
- Segment focus: Gilead Sciences, Inc. has 5 segments (68.5% in HIV); UnitedHealth Group Incorporated has 4 segments (74.9% in UnitedHealthcare).
- Primary market structure: Oligopoly vs Oligopoly. Pricing power: Moderate vs Weak.
- Moat breadth: Gilead Sciences, Inc. has 8 moat types across 3 domains; UnitedHealth Group Incorporated has 5 across 2.
Primary market context
Gilead Sciences, Inc.
HIV
HIV treatment and prevention medicines (antiretroviral therapy and PrEP)
Global (U.S. and Europe are major markets)
Patients/prescribers; reimbursed by public and private payers; distributed via wholesalers and specialty pharmacies
Drug developer and marketing authorization holder
68.5%
UnitedHealth Group Incorporated
UnitedHealthcare
U.S. health benefits / managed care (commercial, Medicare Advantage, Medicaid managed care)
United States (primarily)
Employers, individuals, and government-sponsored programs
Health insurer / managed care organization
74.9%
Side-by-side metrics
Moat coverage
Shared moat types
No overlap yet.
Gilead Sciences, Inc. strengths
UnitedHealth Group Incorporated strengths
Segment mix
Gilead Sciences, Inc. segments
Full profile >HIV
Oligopoly
Oncology (Cell Therapy + Trodelvy)
Oligopoly
Liver Disease
Oligopoly
Veklury (Remdesivir)
Competitive
Other Products
Competitive
UnitedHealth Group Incorporated segments
Full profile >UnitedHealthcare
Oligopoly
Optum Health
Competitive
Optum Insight
Competitive
Optum Rx
Oligopoly
Want the full wide moat stocks list?
Browse the full ranking of wide moat stocks, updated with moat scores and segment context.
View the moat stocks listCuration & Accuracy
This directory blends AI‑assisted discovery with human curation. Entries are reviewed, edited, and organized with the goal of expanding coverage and sharpening quality over time. Your feedback helps steer improvements (because no single human can capture everything all at once).
Details change. Pricing, features, and availability may be incomplete or out of date. Treat listings as a starting point and verify on the provider’s site before making decisions. If you spot an error or a gap, send a quick note and I’ll adjust.